GSK2141795

DRUG5 trials

Sponsors

GlaxoSmithKline, Adil Daud, Dana-Farber Cancer Institute

Conditions

CancerCervical CancerMelanomaSolid Tumours

Phase 1

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

CompletedNCT00920257

GlaxoSmithKlineCancer

Start: 2009-06-16End: 2013-04-17Updated: 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

CompletedNCT01138085

GlaxoSmithKlineCancer

Start: 2010-05-04End: 2014-11-19Updated: 2017-11-13

An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer

CompletedNCT01266954

GlaxoSmithKlineSolid Tumours

Start: 2010-06-01End: 2011-09-01Updated: 2017-11-09

Phase 2

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

CompletedNCT01941927

Adil DaudMelanoma

Start: 2013-09-10End: 2017-05-03Updated: 2020-02-12

GSK1120212+GSK2141795 for Cervical Cancer

TerminatedNCT01958112

Dana-Farber Cancer InstituteCervical Cancer

Start: 2013-10-31End: 2017-11-30Updated: 2019-05-31

Related Papers

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

2018-04-0337 citations

Abstract CT142: A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer

Cancer Research2017-07-011 citations

Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma.

Journal of Clinical Oncology2015-05-2014 citations

A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.

Journal of Clinical Oncology2015-05-201 citations